Oncology

ADC Technology Report: Prospects for Next-Generation ADC Development

by
ADC Technology Report: Prospects for Next-Generation ADC Development

Antibody-drug conjugates (ADCs) have become a popular avenue for cancer treatment in recent years. They typically consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs (payloads) through chemically synthesized linkers. ADCs combine the advantages of high specificity targeting and effective killing action, achieving precise and efficient elimination of cancer cells. Figure 1. Structure and … Read more

Overview of ADC Drug Development Landscape

by
Overview of ADC Drug Development Landscape

Antibody-drug conjugates (ADC) are also known as “biological missiles”. They connect cytotoxic drugs similar to chemotherapy with monoclonal antibodies, consisting of three parts: antibodies, linkers, and payloads (small molecule cytotoxic drugs). This combination achieves the dual advantages of small molecules and antibody drugs, enabling targeted killing of tumors and other diseases. In recent years, global … Read more

Next Generation Antibody-Drug Conjugates (ADCs): What They Look Like

by
Next Generation Antibody-Drug Conjugates (ADCs): What They Look Like

Antibody-drug conjugates (ADCs) have become an important treatment method in the field of oncology, offering superior clinical characteristics compared to chemotherapy. However, the application of ADCs still faces two significant challenges. First, there are very few validated payloads with proven mechanisms of action (MoA), which limits the expansion of indications. Approved ADC payloads cover three … Read more

How to Use ADCs? Managing Adverse Reactions? Expert Recommendations

by
How to Use ADCs? Managing Adverse Reactions? Expert Recommendations

*For reference by medical professionals only Antibody-drug conjugates (ADCs) have become a new hotspot in the field of anti-tumor therapy, with explorations in the treatment of breast cancer, lung cancer, gastric cancer, colorectal cancer, and other types of cancer. With the approval and clinical entry of drugs such as Trastuzumab Deruxtecan, Ado-trastuzumab emtansine, and Enfortumab … Read more

Exploring GeoMx DSP Applications in Cancer Research

by
Exploring GeoMx DSP Applications in Cancer Research

Introduction GeoMx® Digital Spatial Profiler (DSP) is one of the leading revolutionary technologies that elevate spatial biology to new heights and is a core force in driving the forefront of spatial multi-omics research and clinical translation practices. It meets the research and application needs at different stages across various fields such as oncology, tumor immunology, … Read more

VICTORIA Study: Larotrectinib vs Traditional SoC Efficacy Highlights

by
VICTORIA Study: Larotrectinib vs Traditional SoC Efficacy Highlights

Due to the involvement of NTRK gene fusions in various tumors, their occurrence is rare, and the standard therapies (SoC) and prognoses for different tumors vary. Conducting clinical trials of TRK inhibitors using the “gold standard” randomized controlled trials (RCTs) is often impractical. Currently, clinical trials for TRK inhibitors mostly employ single-arm basket study designs … Read more

AAPM 263 Standardized Naming for Radiation Therapy Structures

by
AAPM 263 Standardized Naming for Radiation Therapy Structures

“The Late Spring Festival”! In 2020, as the Mid-Autumn Festival coincided with National Day, each person’s feelings and reflections on the tumultuous past six months and the sense of loss and recovery are countless. As families reunite, let us together remember the past and cherish the present! The National Day holiday is already halfway through. … Read more

Developing ADCs in the Post-DS-8201 Era: Future Perspectives

by
Developing ADCs in the Post-DS-8201 Era: Future Perspectives

The 4th Global Biopharmaceutical Frontier Technology Conference and Exhibition is Open for Registration! The story of the “magic bullet” ADC has clearly not reached its final chapter. With the advent of DS-8201, the global ADC market has become exceptionally vibrant, entering a period of rapid growth. The market’s enthusiasm for ADCs is evident from the … Read more

Case Sharing of ADC: A HER2-Positive Breast Cancer Case

by
Case Sharing of ADC: A HER2-Positive Breast Cancer Case

Expert Commentary Professor Feng Jifeng Chief Physician, Professor, Doctoral Supervisor Secretary of the Party Committee, Jiangsu Provincial Cancer Hospital/Nanjing Medical University Affiliated Cancer Hospital Member of the Expert Committee on Rational Drug Use, National Health Commission Council Member of the Chinese Medical Association, Member of the Internal Medicine Group of the Oncology Branch Vice President … Read more

15 ADC Drugs: Usage and Dosage Summary

by
15 ADC Drugs: Usage and Dosage Summary

Currently, 15 ADC drugs have been approved globally, of which 6 are approved in China, namely Enfortumab vedotin, Brentuximab vedotin, Trastuzumab deruxtecan, Gemtuzumab ozogamicin, Sacituzumab govitecan, and Loncastuximab tesirine. This article provides a brief summary of the currently approved ADC drugs, the types of tumors they are suitable for, and how to use them. 1. … Read more